Nicolas Girard

Groupement Hospitalier Est
Lyon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 434 publications

High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.

High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: July 31, 2026

Troponin Screening and Major Cardiovascular Adverse Events During Immune Checkpoint Inhibitor Therapy.

Troponin Screening and Major Cardiovascular Adverse Events During Immune Checkpoint Inhibitor Therapy.

Journal: JAMA network open

Published: July 21, 2026

Dissociated skeletal response to first-line immunotherapy in synchronous bone metastatic non-small cell lung cancer patients: Clinical profiles and survival benefit of denosumab adjunction.

Dissociated skeletal response to first-line immunotherapy in synchronous bone metastatic non-small cell lung cancer patients: Clinical profiles and survival benefit of denosumab adjunction.

Journal: Journal of bone oncology

Published: July 08, 2026

Endomyocardial Biopsy in Suspected Immune Checkpoint Inhibitor-Myocarditis: Histologic Spectrum and Correlations With Clinical and Cardiac Magnetic Resonance Features.

Endomyocardial Biopsy in Suspected Immune Checkpoint Inhibitor-Myocarditis: Histologic Spectrum and Correlations With Clinical and Cardiac Magnetic Resonance Features.

Journal: Journal of the American Heart Association

Published: June 23, 2026

Treatment patterns and outcomes in advanced and metastatic lung cancer in France: Results from the Epidemiological Strategy and medical Economics (ESME) database lung cancer in France.

Treatment patterns and outcomes in advanced and metastatic lung cancer in France: Results from the Epidemiological Strategy and medical Economics (ESME) database lung cancer in France.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 16, 2026

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 26, 2026

First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.

First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.

Journal: The New England journal of medicine

Published: April 15, 2026

High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.

High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.

Journal: medRxiv : the preprint server for health sciences

Published: April 10, 2026

SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.

SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.

Journal: Future oncology (London, England)

Published: April 06, 2026

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

Journal: The Lancet. Oncology

Published: March 20, 2026

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study.

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study.

Journal: Oncology and therapy

Published: March 06, 2026

Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.

Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 03, 2026

Showing 1-12 of 434

Last Updated: 09/26/2026